Ortho Clinical Diagnostics - a Johnson & Johnson Company.
Global Sites:  India (English)

Skip navigation links
Register for Updates ›
    
Technology that drives the science of knowing. Technology that drives the science of knowing.

Technology that drives the science of knowing.

 

RhoGAM® Rho(D) Immune Globulin (Human) |

 

FETALSCREEN™ II FMH Test  |  RhoGAM® Rho(D) Immune Globulin (Human)  

  

 

 

Before the introduction of RhoGAM® Brand in 1968, roughly 10,000 babies died each year in the U.S. alone from Hemolytic Disease of the Newborn.

 

Today, this condition has been virtually eliminated, saving hundreds of thousands of newborns from crippling birth defects and death. Millions of doses of RhoGAM® Brand have been administered to Rh-negative mothers worldwide, and Ortho Clinical Diagnostics has provided nearly 40 years of uninterrupted supply to protect even the tiniest patients.

 

For more detailed information regarding the safe and effective use of RhoGAM® Brand please see the full prescribing information

 

Important Safety Information


RhoGAM® and MICRhoGAM® Ultra-Filtered PLUS Rho(D) Immune Globulin (Human) are made from human plasma. Since all plasma-derived products are made from human blood, they may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent. RhoGAM® and MICRhoGAM® are intended for maternal administration. Do not inject the newborn infant. Local adverse reactions may include redness, swelling, and mild pain at the site of injection and a small number of patients have noted a slight elevation in temperature. Patients should be observed for at least 20 minutes after administration. Hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. RhoGAM® and MICRhoGAM® contain a small quantity of IgA and physicians must weigh the benefit against the potential risks of hypersensitivity reactions. Patients who receive RhoGAM® and MICRhoGAM® for Rh-incompatible transfusion should be monitored by clinical and laboratory means due to the risk of a hemolytic reaction.

 

Request Product Information

 

Complete Prescribing Information for RhoGAM® Ultra-Filtered PLUS

 

For more information, click here to go to RhoGAM.com

 

© All contents copyright Ortho Clinical Diagnostics, 2003-2011 unless otherwise noted. This site is published by Ortho Clinical Diagnostics a division of Johnson & Johnson Limited, which is solely responsible for its contents. Product availability is subject to fulfillment of regulatory requirements in each market.  This site was written for healthcare professionals in India only.

Last Modified Date: 07-04-2010 09:05